echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Issued by the national health and Health Commission to carry out drug use monitoring and clinical comprehensive evaluation

    Issued by the national health and Health Commission to carry out drug use monitoring and clinical comprehensive evaluation

    • Last Update: 2019-04-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On April 9, the Department of drug policy and basic drug system issued the notice of the national health and Health Commission on drug use monitoring and clinical comprehensive evaluation (hereinafter referred to as the notice) According to the document, the state should comprehensively carry out drug use monitoring, improve the national drug policy, improve the ability of drug supply guarantee, and promote scientific, reasonable and safe drug use The drug use monitoring system covers a wide range, and the key monitoring public institution documents mention to establish a national and provincial drug use monitoring platform and a national, provincial, prefecture, and county level drug use monitoring network, so as to realize the functions of drug use information collection, statistical analysis, information sharing, etc., and to cover public medical and health institutions at all levels At the same time, the key points of monitoring work should be combined and promoted by classification, that is: first, comprehensive monitoring should be carried out, and all public medical and health institutions should actively cooperate as required to systematically collect and report information such as drug allocation varieties, production enterprises, quantity used, purchase price, supply and distribution Second, focus on monitoring At least 1500 public medical and health institutions at all levels in the country will be selected On the basis of comprehensive monitoring, focus on monitoring the specific data related to drug use, disease prevention and follow-up We will focus on key areas and implement them step by step In 2019, the first phase of the national health insurance information project pilot provinces, pilot cities for centralized drug purchase organized by the state, and key monitoring medical and health institutions in each province (District, city) should focus on the national basic drugs, special drugs for anti-cancer drug price reduction and pilot varieties for centralized drug purchase organized by the state, and carry out drug use monitoring as required In 2020, the monitoring scope will basically cover public medical institutions at or above the second level, and extend to grass-roots medical and health institutions, gradually realizing the monitoring of all equipped and used drugs The results of the comprehensive clinical evaluation of drugs affect the "notice" on drug procurement, which points out that promoting the comprehensive clinical evaluation of drugs is one of the key work The relevant departments at the national and provincial levels shall organize and carry out comprehensive evaluation around the selection of national essential drug catalogue, encouraging generic drug catalogue, encouraging research and development and application of children's drug list, etc According to the national deployment arrangement and relevant guidelines and specifications, the provincial health administration department shall take into account the drug supply guarantee and use demand of the jurisdiction, organize superior forces and carry out comprehensive evaluation according to local conditions We will encourage medical institutions, scientific research institutes, trade associations and other institutions to conduct comprehensive evaluation on the safety, effectiveness and economy of clinical use of drugs in combination with basic accumulation, technical expertise and clinical drug demand When carrying out the comprehensive clinical evaluation of drugs, medical and health institutions at all levels should make full use of the monitoring data of drug use, and take the evaluation results as the important basis for the formulation of drug purchase catalogue, the rational clinical use of drugs, the provision of pharmaceutical services, and the control of unreasonable drug expenses The clinical value of drugs is the key, and the "day" of auxiliary drugs is hard! According to the notice, relevant departments are required to make full use of relevant information according to actual needs, and conduct qualitative and quantitative data integration analysis around the safety, effectiveness, economy, innovation, suitability, accessibility, etc of drugs At the same time, the provincial health administrative department shall summarize and analyze the comprehensive clinical evaluation of the jurisdiction once a year, and timely grasp the promotion and implementation of the comprehensive evaluation of medical institutions and relevant technical institutions within the jurisdiction In addition, the notice also requires medical institutions to link up drug purchase with drug use of superior and subordinate medical institutions, constantly optimize the drug use structure of medical institutions, and improve the level of safe and rational drug use This regulation has the same effect with the key drug monitoring work in Jiangxi Province According to the key monitoring catalogue issued by the province, drug use connection has been established from top to bottom, from 20 at the provincial level, 20 at the municipal level, 20 at the municipal level, 20 at the municipal level, and 41 at the county level From the above policy points of view, once the drug use monitoring and clinical comprehensive evaluation work is carried out, the first to be affected must be auxiliary drugs Although the primary varieties of adjuvants have not been announced, the prelude to strict control of adjuvants has been sounded Information source: statement of the national health and Health Commission: the viewpoint of this article only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.